Joana  Goncalves net worth and biography

Joana Goncalves Biography and Net Worth

Insider of Cara Therapeutics
Dr. Goncalves brings more than 17 years of leadership experience in the biopharmaceutical industry to Cara. Most recently, she served as Vice President, Medical Affairs for Dermatology and Neurology at Celgene Corporation where she was instrumental in planning and executing medical support activities for a number of programs, including OTEZLA® for psoriasis. Previously, Dr. Goncalves held the position of Vice President, Medical Strategy and Scientific Affairs at LEO Pharma Inc., the U.S. subsidiary of LEO Pharma A/S. She began her pharmaceutical career at Novartis Pharmaceuticals, working on a range of products across various therapeutic areas. Dr. Goncalves received her M.D. from the University of Cape Town, South Africa.

What is Joana Goncalves' net worth?

The estimated net worth of Joana Goncalves is at least $37,088.68 as of April 5th, 2024. Dr. Goncalves owns 53,365 shares of Cara Therapeutics stock worth more than $37,089 as of April 24th. This net worth approximation does not reflect any other assets that Dr. Goncalves may own. Additionally, Dr. Goncalves receives a salary of $747,250.00 as Insider at Cara Therapeutics. Learn More about Joana Goncalves' net worth.

How old is Joana Goncalves?

Dr. Goncalves is currently 50 years old. There are 4 older executives and no younger executives at Cara Therapeutics. The oldest executive at Cara Therapeutics is Mr. Scott M. Terrillion, Chief Compliance Officer, General Counsel & Corporate Secretary, who is 61 years old. Learn More on Joana Goncalves' age.

What is Joana Goncalves' salary?

As the Insider of Cara Therapeutics, Inc., Dr. Goncalves earns $747,250.00 per year. The highest earning executive at Cara Therapeutics is Mr. Christopher A. Posner, President, CEO & Director, who commands a salary of $1,200,000.00 per year. Learn More on Joana Goncalves' salary.

How do I contact Joana Goncalves?

The corporate mailing address for Dr. Goncalves and other Cara Therapeutics executives is 107 ELM STREET 9TH FLOOR, STAMFORD CT, 06902. Cara Therapeutics can also be reached via phone at (203) 406-3700 and via email at [email protected]. Learn More on Joana Goncalves' contact information.

Has Joana Goncalves been buying or selling shares of Cara Therapeutics?

In the last ninety days, Joana Goncalves has sold $2,284.99 in Cara Therapeutics stock. Most recently, Joana Goncalves sold 2,753 shares of the business's stock in a transaction on Friday, April 5th. The shares were sold at an average price of $0.83, for a transaction totalling $2,284.99. Following the completion of the sale, the insider now directly owns 53,365 shares of the company's stock, valued at $44,292.95. Learn More on Joana Goncalves' trading history.

Who are Cara Therapeutics' active insiders?

Cara Therapeutics' insider roster includes Derek Chalmers (CEO), Joana Goncalves (Insider), Jeffrey Ives (Director), Frederique Menzaghi (SVP), Christopher Posner (Pres), Thomas Reilly (CFO), Scott Terrillion (Insider), and Martin Vogelbaum (Director). Learn More on Cara Therapeutics' active insiders.

Are insiders buying or selling shares of Cara Therapeutics?

In the last year, insiders at the biopharmaceutical company sold shares 10 times. They sold a total of 74,015 shares worth more than $85,004.00. The most recent insider tranaction occured on April, 5th when insider Joana Goncalves sold 2,753 shares worth more than $2,284.99. Insiders at Cara Therapeutics own 4.2% of the company. Learn More about insider trades at Cara Therapeutics.

Information on this page was last updated on 4/5/2024.

Joana Goncalves Insider Trading History at Cara Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/5/2024Sell2,753$0.83$2,284.9953,365View SEC Filing Icon  
1/17/2023Sell2,265$10.81$24,484.6567,371View SEC Filing Icon  
12/21/2022Sell2,992$11.27$33,719.8471,901View SEC Filing Icon  
11/1/2021Sell1,000$17.15$17,150.00View SEC Filing Icon  
10/27/2021Sell1,000$15.00$15,000.00View SEC Filing Icon  
4/21/2021Sell3,000$27.63$82,890.0043,610View SEC Filing Icon  
3/22/2021Sell3,000$19.65$58,950.0030,610View SEC Filing Icon  
1/21/2021Sell2,000$20.12$40,240.0028,075View SEC Filing Icon  
12/21/2020Sell2,000$15.00$30,000.0027,373View SEC Filing Icon  
11/23/2020Sell2,000$15.31$30,620.0029,373View SEC Filing Icon  
11/10/2020Sell2,000$15.00$30,000.0031,373View SEC Filing Icon  
10/20/2020Sell2,000$15.00$30,000.0033,373View SEC Filing Icon  
6/12/2020Sell10,627$15.05$159,936.3546,000View SEC Filing Icon  
See Full Table

Joana Goncalves Buying and Selling Activity at Cara Therapeutics

This chart shows Joana Goncalves's buying and selling at Cara Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Cara Therapeutics Company Overview

Cara Therapeutics logo
Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.
Read More

Today's Range

Now: $0.67
Low: $0.66
High: $0.72

50 Day Range

MA: $0.83
Low: $0.57
High: $1.05

2 Week Range

Now: $0.67
Low: $0.50
High: $4.67

Volume

170,513 shs

Average Volume

646,902 shs

Market Capitalization

$36.46 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.7